Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camlipixant pharmacokinetics in hepatic impairment
NCT06222892Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of camlipixant in cough (4 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity at 96 hours and Maximum Observed Plasma Concentration at 96 hours. Started Feb 2024; status: completed.
02
Drugs
camlipixant
03
Conditions
cough
Beyond the preview
Go deeper on NCT06222892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222892.